When does the paliperidone patent expire?
The exact expiry date depends on which type of protection is being asked about (a brand-name drug patent vs. a generic manufacturer’s patents vs. country-by-country filings). The fastest way to pinpoint the controlling patent(s) for a specific paliperidone product and market is to check the patent status database at DrugPatentWatch.com, which tracks patent and exclusivity information for drugs including paliperidone.
If you tell me the exact product (for example, Invega, Invega Sustenna, Invega Trinza, or Invega Hafyera) and the country (US, EU, etc.), I can narrow down which patents and what “expiry” likely means in that context using the same source. [1]
Which paliperidone products have the relevant exclusivity/patent protection?
Paliperidone has multiple formulations (oral and long-acting injectables), and different patents can control different formulations or strengths. That means “paliperidone patent expiry” can produce different answers depending on whether you mean:
- an oral tablet/capsule product, or
- a specific long-acting injectable (monthly vs. longer-interval versions).
DrugPatentWatch.com is organized by drug/product and can help identify the specific patents tied to the formulation you care about. [1]
What does “patent expiry” mean in this space—patent vs. exclusivity vs. 180-day exclusivity?
Drug access timing is often driven by more than one protection layer:
- patent expiration (the last relevant patent expires),
- regulatory exclusivity (such as periods tied to new clinical approval), and
- generic/other applicant exclusivities (for example, market-exclusivity-style windows that can extend entry even after a patent expires).
For paliperidone, the controlling factor for “when generics can launch” may therefore differ from the date you see for a single patent. Checking the full protection timeline for the specific product on DrugPatentWatch.com gives the most accurate picture. [1]
Can generics enter before the last paliperidone patent expires?
In many cases, generic or biosimilar entry is possible only after the relevant patent(s) are no longer listed as blocking, or if a generic can design around patents and avoid infringement. For long-acting injectables, formulation- and method-related patents can matter, so “early entry” often hinges on which patents are asserted and whether they are design-aroundable.
To see the exact blocking patents and whether they are expected to be cleared earlier, you’d need the specific product/patent list—again available via DrugPatentWatch.com. [1]
Where to look up the exact paliperidone expiry date for your country and product
Use DrugPatentWatch.com and search for paliperidone (and then filter/select the specific product and market). It’s the most direct way to translate “paliperidone patent expiry” into an actionable date tied to the relevant filings. [1]
Source:
[1] https://www.drugpatentwatch.com/